A study looking at inhaled pirfenidone for people with progressive pulmonary fibrosis

Upcoming study
Expected to open
This study is currently recruiting
Expected to close
This study is closed
This study closed in
We will update this page with study results when available.
Information on study results are included below
This study closed in
Ask your healthcare team about taking part in research

What next?

Original listing:

What next?

Original listing:

About this study

Pirfenidone is an approved treatment for pulmonary fibrosis in tablet form. Higher doses are needed for the ingredients of a tablet to reach the lungs. These high doses can be associated with significant side effects.

Initial studies in patients with idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF) suggest that inhaled pirfenidone may reduce side effects and still help to slow the progression of the disease.

This study aims to investigate if inhaled pirfenidone reduces side effects and helps to slow the progression of the disease for people with PPF.


What is involved?

You will be randomly put into 1 of 3 groups.

  • Group 1 will be given a high dose of inhaled pirfenidone twice per day
  • Group 2 will be given a low dose of inhaled pirfenidone twice per day  
  • Group 3 will be given a placebo twice per day. This is a look alike treatment and will not contain any pirfenidone.

The treatment is provided through a nebuliser. You will receive training for how to use this at the first hospital visit. You will have regular contact with the research team through telephone calls and hospital visits.

You will be asked to have lung function tests, high-resolution computed tomography (HRCT) scans and other medical monitoring at various points throughout the study. You will also be asked to complete questionnaires.

Summary of involvement

Using a nebuliser twice per day

Lung function tests

HRCT scans

Other medical monitoring


Can I take part?

You may be able to take part if you have a diagnosis of Progressive Pulmonary Fibrosis (PPF) and are aged 18 years and older. You may be able to take part if you are currently prescribed nintedanib.

In research studies, there are lots of different reasons why you may or may not be able to take part. These are known as inclusion and exclusion criteria (see list below). Only the research team will be able to fully determine whether you are able to take part in the study. You can withdraw at any point.

If you are not able to take part in this research study, there may be other opportunities for you to take part in different studies.

To find our more about other research opportunities visit our research finder main page.

You may be able to join this study if all of these apply:

Diagnosis of Progressive Pulmonary Fibrosis (PPF)

Aged 18 years or older

Meet spirometry test requirements and other study requirements explained by the study doctor.

You can be taking nintedanib if a stable dose is already prescribed by your doctor

You will not be able to join the study of any of the following applies:

Diagnosis of Idiopathic Pulmonary Fibrosis

Current or very recent treatment with oral pirfenidone

Significant liver or kidney disease

A greater extent of emphysema than fibrotic lung disease on CT scan

Significant non PPF disease such as cancer, very high blood pressure or a heart attack or unstable angina within the previous 6 months

Pulmonary Hypertension

What difference could taking part make?

Taking part in this study will help researchers to understand the effects of inhaled pirfenidone on people living with PPF.

Where does the study take place?

Study locations












How to take part

If you would like to find out more about taking part or what research opportunities are available for you, we would encourage you to ask your healthcare team.

You can also find out more about the study on the Avalyn Pharma website, or email the research team directly via: MISTPPFStudy@avalynpharma.com if you have any specific questions about the study.

Further information

This page is a summary which provides information about an opportunity to participate in research. More detailed information about the study can be found via the following the links and through contacting the research team.

If you have any questions about this research study, please speak to your medical team.


This study is supported by

Avalyn Pharma
Study ID number:

APF does not endorse or recommend any specific study. All responsibility for the study remains with the sponsors and investigators.

Every effort is made to keep these details up to date. If you are aware of any inaccuracies, please email research@actionpf.org